Tonix Pharma Details Positive TNX-4800 Lyme Disease Data, Outlines Phase 2 Study
TNXP sits 19% above its 52-week low of $11.603.
Summary
Tonix Pharmaceuticals released detailed positive Phase 1 data for its Lyme disease candidate TNX-4800, supporting a long-acting regimen and outlining plans for a Phase 2 study in 2027.
Key Events · Product Development and Regulatory · TNXP
-
Detailed Phase 1 Pharmacokinetic Data
Simulations from the Phase 1 trial of TNX-4800 predict that a two-dose regimen can maintain protective serum levels (above 10 µg/mL) for up to six months, supporting its potential as a long-acting prophylactic for Lyme disease.
-
Planned Adaptive Phase 2 Study
The company plans to initiate an adaptive Phase 2 field study for TNX-4800 in the first half of 2027, pending agreement from the U.S. Food and Drug Administration.
-
FDA Meeting Scheduled
A Type C meeting with the FDA is scheduled for early Q3 2026 to discuss the planned Phase 2 study design for TNX-4800.
-
Favorable Safety Profile Confirmed
The Phase 1 study confirmed TNX-4800 was safe and well-tolerated, with dose-proportional pharmacokinetics and a mean half-life of 62-69 days.
Analysis · TNXP · Life Sciences
This 8-K provides detailed pharmacokinetic data from the Phase 1 trial of TNX-4800, a prophylactic for Lyme disease, demonstrating its potential for long-acting protection. The company also outlined plans for an adaptive Phase 2 field study in 1H 2027, including a scheduled FDA meeting. This progress in a key pipeline asset is crucial for Tonix, which has recently reported significant losses and a 'going concern' warning, offering a potential path to future revenue.
At the time of this filing, TNXP was trading at $13.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $224.6M. The 52-week trading range was $11.60 to $69.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.